Abstract:Objectives: To prospectively compare the effects on heart rate (HR) and contrast enhancement efficacy of iopamidol-370 and iodixanol-320 in contrast-enhanced, multidetector-row computed tomography (CE-MDCT).Methods: IMPACT is a multicenter, double-blind study involving 166 patients undergoing CE-MDCT of the liver (n = 121) or peripheral arteries (n = 45) randomized to receive equi-iodine doses (40 gI) of iopamidol-370 or iodixanol-320 intravenous at 4 mL/s. CE-MDCT was performed using 16-MDCT scanners according to predefined imaging protocols. HR was measured with the patient in the supine position before and continuously for 5 minutes after contrast medium administration. Mean and peak increases in HR and the proportion of subjects with predefined HR increases (>5 to <10, 10 to <15, 15 to <20, >20 bpm) were compared in the 2 populations. Liver images were assessed by 2 independent, blinded readers for contrast enhancement [Hounsfield unit (HU)], using predefined regions-of-interest during the arterial and portal-venous phase of enhancement.Results: Effects on HR: Eighty-four subjects received iopamidol-370 whereas 82 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, dose/body weight, concomitant medications and use of beta-blockers were comparable in the 2 groups. Mean baseline HR was similar in the 2 groups (iopamidol-370: 72.3 +/- 12.5 bpm; iodixanol-320: 74.5 +/- 11.9 bpm). Mean changes from baseline to peak postdose were similar in the 2 groups (8.0 +/- 9.3 bpm after iopamidol-370 and 8.4 +/- 14.7 after iodixanol-320, P = 0.72). The proportion of subjects in each group having increases of <5, >5 to <10, 10 to <15, 15 to <20, or >20 bpm was comparable (P = 0.87). Two subjects experienced postcontrast tachycardia (HR increase >70 bpm, peak HR of 146 and 164 bpm), both in the iodixanol-320 group (2.4%). Contrast Enhancement: Of the 121 patients undergoing liver CT, 60 received iopamidol-370 whereas 61 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, and dose/body weight were comparable in the 2 groups. Iopamidol-370 provided significantly higher HU values in abdominal aorta during the arterial phase of enhancement for both readers [R1: 301.3 +/- 80.2 vs. 273.6 +/- 65.9 HU, 95% confidence interval (6.1 - 56.8), P = 0.02; R2: 302.0 +/- 73.6 vs. 275.1 +/- 62.9 HU, 95% confidence interval (2.3 - 51.3), P = 0.03]. No significant difference was observed between the 2 contrast medium during the portal venous phase of enhancement.Conclusions: When the same injection rate and iodine dose is used, the effects on HR of bolus intravenous injections of iopamidol-370 and iodixanol-320 were similar. Iopamidol-370 provides significantly greater enhancement during the arterial phase and similar enhancement during the portal venous phase compared with iodixanol-320.

Differential effects of three radiographic contrast media on platelet aggregation and degranulation: implications for clinical practice?

Effects of intravenous radiographic contrast media on the blood pressure and on factors of the contact activation system in the rat

The effects of non-ionic contrast medium on the hemorheology in vitro and in vivo.

Renal Tolerability of Iopromide and Iodixanol in 562 Renally Impaired Patients Undergoing Cardiac Catheterisation: the Direct Study

Iodine based radiopacity of experimental blood clots for testing of mechanical thrombectomy devices

Effects of a novel low volume resuscitation solutions on coagulation and platelet function

In vitro investigation the effects of iodinated contrast media on endothelial cell viability, cell cycle, and apoptosis

High-volume Nonionic Dimeric Contrast Medium: First Experiences During Complex Coronary Interventions

Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]

[The Effect of Different Loading Doses of Clopidogrel on Platelet Aggregation].

Effect of iodinated contrast media on peripheral blood mononuclear cells in terms of cell viability, cell cycle and oxidative stress in an in vitro system

Adverse skin reactions to iodinated x-ray contrast agents in healthy rats

Iso-Osmolar Iodixanol Induces Less Increase in Circulating Endothelial Microparticles in Vivo and Less Endothelial Apoptosis in Vitro Compared with Low-Osmolar Iohexol.

A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

A Comparison of the Efficacy and Safety of Iopamidol-370 and Iodixanol-320 in Patients Undergoing Multidetector-Row Computed Tomography.

The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count

Antiplatelet effect of the anaesthetic drug propofol: influence of red blood cells and leucocytes

Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model

Effects of two different hydroxyethyl starch solutions (HES200/0.5 vs. HES130/0.4) on the expression of platelet membrane glycoprotein.

Renal adverse effect of intravenous administration of iodixanol (270mg I/ml)

A Comparison of the Efficacy and Safety of Iopamidol-370 and Iodixanol-320 in Patients Undergoing Multidetector-Row Computed Tomography